January 23rd 2024
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
December 26th 2023
Diagnostic Immunoassays Could Spare Patients High-Risk Pancreatic Resection
June 25th 2017Researchers at Indiana University have confirmed the clinical utility of 2 laboratory tests that can distinguish benign pancreatic cancer lesions that mimic early signs of cancer and spare patients of unnecessary pancreatic cancer screenings or surgeries.
Read More
FDA Approves Rituxan Hycela for Treating Certain Blood Cancers
June 24th 2017The FDA has approved Genentech’s Rituxan Hycela for subcutaneous injection for the treatment of certain blood cancers. Rituxan Hycela has similar outcomes as Rituxan, but can be delivered in 5 to 7 minutes compared with 1.5 hours for Rituxan.
Read More
Genentech's Ocrevus Reduces Disease Progression in Multiple Sclerosis Patients
June 23rd 2017A phase 3 clinical trial of patients with relapsing multiple sclerosis and primary progressive multiple sclerosis found that Ocrevus (ocrelizumab) significantly reduced disease progression, according to results released by Genentech.
Read More
FDA Approves of Darzalex Combination for Multiple Myeloma
June 23rd 2017The FDA has approved the use of Janssen Biotech, Inc’s immunotherapy Darzalex in combination with pomalidomide and dexamethasone. Darzalex is used to treat multiple myeloma patients who have previously received at least 2 therapies with lenalidomide and a proteasome inhibitor.
Read More
Genome-Wide Association Studies Identify Novel Risk Loci for Testicular Cancer
June 14th 2017A meta-analysis spearheaded by The International Testicular Cancer Consortium has identified new susceptibility loci in the human genome that can increase a person’s risk of developing inherited testicular germ cell tumors.
Read More
Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma
June 7th 2017A phase 1 study, presented at the 2017 American Society of Clinical Oncology Annual Meeting, found that including daratumumab can improve patient response to treatment in newly diagnosed multiple myeloma.
Read More
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 5th 2017Updated results from the POLLUX and CASTOR trials, presented at the 2017 American Society of Clinical Oncology Annual Meeting, have found that including daratumumab in standard-of-care regimens prolonged progression-free survival (PFS) and improved the depth of response, independent of the patients’ cytogenetic risk.
Read More
Cost Burden of Managing Duchenne Muscular Dystrophy and Disease Progression
June 2nd 2017Healthcare costs for patients with Duchenne muscular dystrophy (DMD) are already far higher than for individuals without the disease, and a new study has found that total healthcare costs are also higher for older patients with DMD.
Read More
Overcoming Barriers to Treatment for Patients With Cystic Fibrosis
June 1st 2017Patients with cystic fibrosis face a lifetime of time-consuming treatment. There are new breakthrough therapies that not only treat symptoms of the disease, but also the underlying causes, which represents a source of hope for patients. However, barriers to treatment still stand in the way, according to a new white paper from the Cystic Fibrosis Engagement Network.
Read More
Survival Inequalities in Childhood Leukemia Remain Large Worldwide, Despite Progress
May 11th 2017While global inequalities for survival of childhood leukemia have narrowed, the gap remains wide for acute lymphoblastic leukemia and acute myeloid leukemia, according to a study published in The Lancet Haematology. In some countries, the 5-year survival rate is nearly twice as high as in others for children diagnosed in 2005-2009.
Read More
WHO Taps Into Biosimilars for Access to Expensive Cancer Drugs in Poor Nations
May 4th 2017The World Health Organization (WHO) has announced a pilot project that will take advantage of expected savings from biosimilar medications, particularly expensive anticancer agents, to make these treatments available for low- and middle-income countries.
Read More
UConn to Initiate a Personalized Vaccine Trial to Prevent Relapse in Advanced Ovarian Cancer
April 24th 2017The University of Connecticut has initiated recruitment for a phase I trial to test the safety and efficacy of OncoImmunome, a personalized vaccine designed to prevent relapse in patients diagnosed with Stage III or IV ovarian cancer.
Read More
Australian Study Details Diagnosis Delays for Children With Rare Diseases
April 20th 2017Despite the wide variety of rare diseases out there, children and families living with rare disease have one thing in common: they experience diagnostic delays. A new study in Orphanet Journal of Rare Diseases described experiences of seeking and receiving a diagnosis of a rare disease and access to healthcare.
Read More
Dr Aimee Tharaldson Discusses 2 New Treatments for Tardive Dyskinesia
April 12th 2017The market for tardive dyskinesia, a movement disorder affecting 500,000 patients in the United States, will go from zero approved treatments to 2 in 2017, making it an important area to watch, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.
Watch
AACR Study Finds Shift in Cancer Burden in HIV-Positive Individuals
April 6th 2017A study presented at the annual meeting of the American Association for Cancer Research predicts a shift in the number and the pattern of cancer incidence among those infected with the human immunodeficiency virus (HIV).
Read More